Andrew Meadow

Partner & Chief Investment Officer

Health Innovation Capital · Boston, Massachusetts and Montreal Canada

Present

Health Innovation Capital ("HIC") is a venture capital impact fund whose investment thesis targets the unmet medical needs of pediatric patients in the areas of oncology, infectious diseases, and select rare and orphan designations. To reinforce the firm's impact investment mandate and ESG strategy, HIC established The Health Innovation Capital Foundation to parallel our traditional venture capital allocation and portfolio management strategy. The Foundation is a not-for-profit vehicle from which HIC donates a significant percentage of the firm's General Partner Carried Interest to centers of pediatric research and care excellence. The intended use of this donation is to support the growth and maturation of early stage medical innovations that have the potential to address the unmet care needs of pediatric patients- irrespective of geography and economic circumstance.

Partner

International Cancer Impact Fund (ICIF) · Greater Boston

Partner

Excelyrate Capital · Cambridge, MA

Grant and Program Reviewer

National Institute of Health · Bethesda Maryland

One of 25 researchers, Key Opinion Leaders, and executives selected nationally to review research grant funding requests in the areas of Male and Female Reproductive Health by the National Institute of Health

Chief Strategy Officer (Commercial Strategy, Sales Operations, and Business Development)

Conceivex, Inc. · Greater Detroit Area

Led the commercial roll-out of the first FDA approved device for both male and female infertility Managed all business development and corporate finance activities as well as creating, and executing the strategic plans underpinning Conceivex’s commercial operations, sales role out, and growth Executed all search and evaluation initiatives associated with New Product Acquisitions, joint ventures, and alliances; managed and served as the central contract in the identification, due diligence, and negotiation of 2 strategic partnership initiatives related to global commercial operation expansion and commercial risk mitigation Created and maintained all financial models and valuation analysis underpinning business development transactions and corporate strategy initiatives; Developed dash board reporting platforms to support commercial analytic, consumer insight, unit sales and behavioral economic models that supported the commercial roll-out; Developed and rolled-out direct strategic sales…

Director, Medical Device and Biotech Venture Investments

Michigan Economic Development Corporation

Co-managed the investment and product portfolio of over $450 MM in invested capital into the state’s medical technology and biotech sectors; Worked with both venture funds, entrepreneurs, and existing portfolio companies to make direct investments into the MedTech and Biopharmaceutical sectors Achieved 1 IPO, 2 strategic alliances, and 5 principal investor financings totaling over $150MM in net proceeds for the state’s portfolio companies within the medical technology and biotech sectors Worked lockstep with entrepreneurs and investors to mitigate product, regulatory, market access, and reimbursement risk associated with an investment’s product maturation and portfolio growth Lead the identification, deal sourcing, and evaluation of new investment opportunities, deal structuring, and the negotiation of exit strategies that provided investors with a positive cash on cash return Evaluated product roll-up strategies that would complement existing pipeline and commercial portfolio; Assiste…

Principal

Management Consulting (Business Development, Alliance Management, and Corporate Strategy) · Chicago, Detroit, and Morristown, New Jersey

Global strategic consulting to Fortune 100 biopharmaceutical and medical technology companies in the areas of: * Business development * Alliance management * Pipeline planning and product acquisition (opportunity search, evaluation, and due diligence) * Valuation, economic analysis, and financial engineering * Co-development joint-ventures and partnerships * New product and market access planning * Primary Market research (consumer, managed care, physician, and payer insight analysis) * Opportunity assessment, deal structuring, counterparty negotiations, and term sheet execution Therapeutic areas of focus include: * Oncology * Neurology * Gastroenterology * Women’s Health * Dermatology * Oral Care * Pulmonology

Vice President: Commercial Operations and Business Development

SkinAxis, Inc. a Division of The Avicena Group · Palo Alto, California

Subsidiary of the Avicena Group, a leading developer of neurological and neuromuscular disease treatments that was spun out of Stanford University; SkinAxis leveraged parents’ IP to focus on a FDA approved dermatology product portfolio SUCCESSFUL EXIT: The SkinAxis portfolio was acquired in 2009 at a 4x multiple of Gross Sales I identified all aspect of the sell side transaction from origination and due diligence to deal structuring, negotiations, and execution. Responsible for originating and executing all business development and corporate strategy initiatives including search and evaluation of new opportunities as well as the establishment of global corporate alliances to assist with broader commercial launch. Created and led the roll-out of all commercial and marketing strategic operations globally Post-product launch, oversaw social and digital media programs to refine marketing tactics and messaging. Leveraged insights to modify sales and marketing strategies—an initiative that y…

Founder and Principal

Meadow Partners, LLC

Manager Corporate Business Development

Baxter Healthcare